Aqueous COX-2 Injectable Composition for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of stable, aqueous parenteral compositions of COX-2 inhibitors like Etoricoxib and Celecoxib, particularly for intravenous administration, due to solubility issues and formulation challenges, which limits their therapeutic applications and administration routes.
Innovation Solution
A pharmaceutical composition using a solvent system with solubilizers such as Transcutol and Tween 80, along with other excipients, to create a clear, stable, and easily administrable injectable solution of COX-2 inhibitors, suitable for various parenteral routes, including intravenous infusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors like Etoricoxib and Celecoxib are formulated for parenteral administration, then therapeutic action is improved, but solubility and stability are worsened
Solution Approach 1:
The patent employs solubilizing agents such as polysorbate 80 and hydroxypropyl beta-cyclodextrin as intermediary substances to bridge the incompatibility between the hydrophobic COX-2 inhibitors and the aqueous injection medium. These agents form inclusion complexes or micellar structures that solubilize the drug molecules, enabling parenteral administration while maintaining stability.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the formulation system by adjusting pH, ionic strength, and using co-solvents to enhance the solubility of COX-2 inhibitors. The formulation optimizes parameters such as maintaining pH between 3-7 and using specific concentrations of solubilizing agents to achieve stable injectable solutions.
2Ease of operation
If a solvent system with solubilizers is used to enhance solubility, then ease of administration is improved, but formulation complexity is worsened
Solution Approach 1:
The patent combines multiple excipients including solubilizing agents, buffers, and stabilizers into a single integrated formulation system. This merging of functional components into one composition simplifies the administration process while achieving multiple objectives of solubility, stability, and biocompatibility simultaneously.
Solution Approach 2:
The formulation uses multi-functional excipients that perform multiple roles: polysorbate 80 acts as both a solubilizing agent and a stabilizer, while hydroxypropyl beta-cyclodextrin provides both solubility enhancement and protection against degradation. This multi-functionality reduces the number of separate components needed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides a stable, ready-to-infuse solution of COX-2 inhibitors with enhanced solubility, enabling prompt therapeutic action and administration via multiple routes, addressing the solubility and stability issues of Etoricoxib and Celecoxib.
Implementation Method 1
A pharmaceutical composition using a solvent system with solubilizers such as Transcutol and Tween 80, along with other excipients, to create a clear, stable, and easily administrable injectable solution of COX-2 inhibitors
Data Source
AI summary
Present invention relates to aqueous compositions comprising cyclooxygenase-2 (COX-2) inhibitors, preferably Etoricoxib or Celecoxib or Valdecoxib or Paracoxib or salts thereof at least two solubilizers at 4.2% w/v to 19% w/v, preferably between 4.2% w/v to 18% w/v having viscosity in range of 1.0 cps to 3 cps, wherein the Etoricoxib and Celecoxib or salts thereof are present in amount ranging from 0.14 mg to 4 mg. The composition is suitable for the parenteral route of administration primarily for ready to dilute and ready to infuse which alternatively can be administered as intramuscular, intraarterial, intraocular, intraventricular, intravenous routes; also for subcutaneous, cutaneous delivery. The invention further provides a method for preparing the said composition.